Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
NCT ID: NCT07076056
Last Updated: 2025-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
230 participants
INTERVENTIONAL
2022-10-27
2024-06-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
NCT01529541
MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)
NCT00289848
Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)
NCT00704132
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
NCT01076075
A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
NCT05403281
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DW1026C1 & DW1026C2 placebo & DW1026S placebo
DW1026C1
Sitagliptin 100mg+Empagliflozin 10mg
DW1026C1 placebo & DW1026C2 & DW1026S placebo
DW1026C2
Sitagliptin 100mg+Empagliflozin 25mg
DW1026C1 placebo & DW1026C2 placebo & DW1026S
DW1026S
Sitagliptin 100mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DW1026C1
Sitagliptin 100mg+Empagliflozin 10mg
DW1026C2
Sitagliptin 100mg+Empagliflozin 25mg
DW1026S
Sitagliptin 100mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 19 ≤ Age ≤ 85
* 7.0% ≤ HbA1c ≤ 10.5%
Exclusion Criteria
* Patients with a history of pre-diabetic coma
* Patients with a history of diagnosis of malignant tumors within 5 years prior to visit 1
19 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewon Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yeouido St. Mary's Hospital The Catholic University
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DW1026-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.